According to reliable sources, the National Institutes of Health on Tuesday affirmed their latest clinical trial to evaluate the outcome of the Covid Booster vaccine. The trial is designed to test already vaccinated candidates with a different vaccine between three to four months.
Sources familiar with the development said the clinical trial would be performed on about 150 adults who have been given a COVID vaccine shot from one particular company. This includes FDA-approved vaccines under its emergency use approval, including Pfizer’s, Johnson & Johnson’s, and Moderna’s vaccine shot.
Director of the National Institute of Allergy and Infectious Diseases, Dr. Anthony Fauci, says, even though the vaccines available in the market currently are enough for providing strong protection against COVID-19, they need to understand the effect of giving an extra dosage to keep up with the evolving nature of the virus. He further added that the outcome of this trial would help in making public health policy decisions for the potential use of mixed doses of vaccines with an extra Booster dose.